Investing

Bristol Myers Squibb : BMY

BMY

Stock Data

$64.70

$0.55 (0.86%)

Asset Type

Common Stock

Exchange

NYSE

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

DRUG MANUFACTURERS - GENERAL

Bristol-Myers Squibb Company is a global biopharmaceutical firm focused on discovering, developing, and delivering innovative medicines for a range of serious diseases. With a rich history dating back to 1887, it specializes in treatments across hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience fields. Its portfolio includes notable drugs like Eliquis, Opdivo, and Sprycel, targeting conditions from cancer to multiple sclerosis. The company markets its products to a variety of clients, including hospitals, pharmacies, and government agencies, aiming to improve patient health outcomes worldwide.

Latest Activity

BMYBristol Myers Squibb

Reports Thu Jul 30Before open6:59 AM ETConfirmed

Jul 30, 2:59am ET

Bristol Myers Squibb reports before the bell as the pharma giant battles patent expirations while racing to prove oncology and immunotherapy bets can sustain growth.

ShareRead more

All Bristol Myers Squibb Articles

596 Articles

Vandita Jadeja | Aug 5, 2026 at 10:00 AM EDT

Prediction: AbbVie Will End The Year at This Price

AbbVie's blockbuster drugs are surging while a major acquisition looms, but a trailing P/E of 71 and one model pricing…

Thomas Richmond | Aug 3, 2026 at 1:17 PM EDT

Top Healthcare Analyst: A $400 Billion AstraZeneca-Bristol Myers Deal Could “Cut Costs in a Big Way”

A Mizuho healthcare analyst says merging two of pharma's biggest names could unlock a fortune, but the math only works…

Gerelyn Terzo | Aug 3, 2026 at 9:18 AM EDT

Live Nasdaq Composite: Stock Market Bulls Wrestle Control to Start August as Oil Drops 6%

Geopolitical relief triggered a sharp selloff in oil and a Treasury retreat, handing bulls an opening to reclaim momentum at…

Lee Jackson | Jul 22, 2026 at 8:40 AM EDT

Bank of America Says the Fed Should Raise Rates Now: 4 Dividend Inflation-Resistant Stocks

Bank of America is breaking with the Fed's wait-and-see approach and pushing for rate hikes now, which reshuffles the entire…

Alex Sirois | Jun 29, 2026 at 10:51 AM EDT

66 With $1.3 Million. Here Are 3 Hidden Gems to Target

At 66 with $1.3 million, the math is straightforward. A 5% blended yield throws off roughly $65,000 a year before…

Alex Sirois | Jun 24, 2026 at 10:02 AM EDT

64 Years Old With $1.1 Million in a Traditional IRA. Here’s Where I’m Allocating Capital

At 64, with $1.1 million in a Traditional IRA, tax-deferred cash flow is the point. With the 10-year Treasury at…

Lee Jackson | Jun 17, 2026 at 8:48 AM EDT

Interest Rates Are Going Higher: 4 High-Yield Passive Income Stocks Can Weather Any Storm

Converging forces are pushing rates higher in 2026. The Iran conflict closed the Strait of Hormuz, spiking crude oil prices…

Michael Williams | Jun 16, 2026 at 6:12 AM EDT

SCHD Now Concentrates 42% of Your Money in Just 10 Stocks. Here Is Who Should Still Own It

Most Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) owners assume they are buying broad market diversification. The latest Schwab fact sheet…

Alex Sirois | Jun 15, 2026 at 10:50 AM EDT

A Dramatic Shift in Fed Policy Just Unlocked a New Era for Bristol Myers Squibb

With the 10-Year Treasury yielding 4.48% and the Fed signaling more cuts ahead, income investors are hunting for yield that…

Vandita Jadeja | Jun 9, 2026 at 2:53 PM EDT

Earn $5,000+ Yearly With These 4 Dividend Stocks

Earned income has a ceiling. Hours in a day, headcount budgets, layoff cycles, and corporate restructurings all cap how much…

Alex Sirois | Jun 7, 2026 at 10:13 AM EDT

Forget Wall Street’s Ultimate Pharma Value Trap: Here Is a Far Better Stock to Buy Right Now

Bristol Myers Squibb (NYSE:BMY | BMY Price Prediction) is the headline pharma name dividend hunters keep circling, drawn in by…

David Beren | Jun 6, 2026 at 12:11 PM EDT

SCHD’s $85 Billion Strategy Now Concentrates 41 Percent of Your Money in Just Ten Stocks

A 63-year-old retiree with $400,000 parked in the Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) likely picked it for the 100-stock…

John Seetoo | May 28, 2026 at 11:44 AM EDT

SCHD’s $71.6 Billion Portfolio Delivers 20% Gains Plus 3.3% Yield This Year

Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) has become one of the most-owned dividend funds in the country, with $71.6 billion…

David Beren | May 22, 2026 at 12:14 PM EDT

Vanguard’s VIG Quietly Returned 247% While Investors Chased Higher Yields

Retirees evaluating dividend funds tend to anchor on current yield, which is exactly why Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) often…

Michael Williams | May 21, 2026 at 7:30 AM EDT

Why retirees are banking on SCHD’s 15-year unbroken dividend streak

The Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) has built its reputation on paying reliable, growing quarterly distributions to income investors,…